Lightmed LightLink CXL, Руководство оператора

Страница: 47 / 56

46
Evidence from ongoing clinical research demonstrates a successful mechanical strength
recovery of the cornea by the cross-linking process, leading to a successful arrest of
keratoconus progression, and increase of corneal rigidity up to 320%.
6.2 Clinical Guidelines
Disclaimer:
The following information has been based on the results of various clinical studies and are
provided with the intention of serving as general guidance only. Corneal Collagen Cross-
Linking with Riboflavin is considered as a revolutionary and still emerging technique under
clinical investigation, it is the ophthalmologist’s responsibility to familiarize themselves with
the latest recommended treatment techniques.
Eligibility and Exclusion Criteria:
Ongoing clinical studies and publications demonstrate the Corneal crosslinking with
Riboflavin as safe and effective treatment indicated for Grades I and II Keratoconus,
Post-Lasik Iatrogenic Ectasia, and Pellucid Marginal Degeneration.
Preoperative patient assessment is still necessary to determine whether a patient with
keratoconus or other corneal disorder is an appropriate candidate for Corneal collagen
Cross-Linking treatment.